Search

Your search keyword '"Powell, Mair"' showing total 17 results
Start Over Author "Powell, Mair"
17 results on '"Powell, Mair"'

1. GBS vaccines in the UK: a round table discussion

Author

Thorn, Natasha, primary, Guy, Rebecca L, additional, Karampatsas, Konstantinos, additional, Powell, Mair, additional, Walker, Kate F, additional, Plumb, Jane, additional, Khalil, Asma, additional, Greening, Vanessa, additional, Eccleston, Emma, additional, Trotter, Caroline, additional, Andrews, Nick, additional, Rush, Lynne, additional, Sharkey, Claire, additional, Wallis, Lauren, additional, Heath, Paul, additional, and Le Doare, Kirsty, additional

Published
2024
Full Text
View/download PDF

2. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates

Author

Mazur, Natalie I, Higgins, Deborah, Nunes, Marta C, Melero, José A, Langedijk, Annefleur C, Horsley, Nicole, Buchholz, Ursula J, Openshaw, Peter J, McLellan, Jason S, Englund, Janet A, Mejias, Asuncion, Karron, Ruth A, Simões, Eric AF, Knezevic, Ivana, Ramilo, Octavio, Piedra, Pedro A, Chu, Helen Y, Falsey, Ann R, Nair, Harish, Kragten-Tabatabaie, Leyla, Greenough, Anne, Baraldi, Eugenio, Papadopoulos, Nikolaos G, Vekemans, Johan, Polack, Fernando P, Powell, Mair, Satav, Ashish, Walsh, Edward E, Stein, Renato T, Graham, Barney S, and Bont, Louis J

Published
2018
Full Text
View/download PDF

4. Use of colistin-containing products within the European Union and European Economic Area (EU/EEA): development of resistance in animals and possible impact on human and animal health

Author

Catry, Boudewijn, Cavaleri, Marco, Baptiste, Keith, Grave, Kari, Grein, Kornelia, Holm, Anja, Jukes, Helen, Liebana, Ernesto, Navas, Antonio Lopez, Mackay, David, Magiorakos, Anna-Pelagia, Romo, Miguel Angel Moreno, Moulin, Gérard, Madero, Cristina Muñoz, Pomba, Maria Constança Matias Ferreira, Powell, Mair, Pyörälä, Satu, Rantala, Merja, Ružauskas, Modestas, Sanders, Pascal, Teale, Christopher, Threlfall, Eric John, Törneke, Karolina, van Duijkeren, Engeline, and Edo, Jordi Torren

Published
2015
Full Text
View/download PDF

5. Antimicrobial resistance in Haemophilus influenzae : epidemiology, mechanisms and therapeutic implications

Author

Powell, Mair

Subjects
616.9
Abstract

Studies with 2,458 clinical isolates of Haemophilus influenzae collected from UK laboratories during 1986 are described. The prevalence and epidemiology of antimicrobial resistance was compared with that in eight European countries as determined by a multi-national survey. Resistance was analysed with reference to difficulties in identification of the species and determination of susceptibility. Mechanisms mediating resistance were investigated. Results from studies with this large collection of isolates often confirmed previously published observations. Beta-lactam susceptibility of 100 isolates possessing non-beta-lactamase-mediated resistance to ampicillin was variable in pattern and degree. Outer-membrane and penicillin-binding protein profiles of resistant wild-types and transformants showed variable agreement with other reports. Biochemical characterisation of chloramphenicol acetyltransferases (CATs) from 42 resistant isolates showed that they resembled Type II enterobacterial enzymes. New information was gathered on prevalence and mechanisms of antimicrobial resistance. Carbapenem activity was shown to be maintained against most ampicillin-resistant beta-lactamase negative isolates and transformants which were of reduced susceptibility to other beta-lactams. Exposure to increasing concentrations of ampicillin selected for mutants with non-beta-lactamase-mediated resistance. Type II CATs from H.influenzae and enterobacteria produced only monoacetylchloramphenicol while Types I and III enzymes produced diacetylated drug at pH 6.8 and pH 7.8 in contrast with previous reports. Polyacrylamide gel electrophoresis was used to separate biochemically characterized dihydrofolate reductases (DHFRs) from trimethoprim-resistant wild-types, mutants and transformants. Results indicated that overproduction of DHFR might be the mechanism of resistance. Data accumulated was used to make recommendations regarding optimal methods for identification of the species and determination of susceptibility in routine diagnostic laboratories. Temporal changes and geographical differences in the prevalence of antimicrobial resistance were considered in making suggestions for appropriate therapy of invasive and non-invasive H.influenzae infections. It was concluded that newly-developed agents must increasingly replace the more traditional antimicrobials as the prevalence of drug resistance in the species continues to rise.

Published
1990

7. Towards earlier inclusion of Children in Tuberculosis (TB) drugs trials: Consensus statements from an Expert Panel

Author

Nachman, Sharon, Ahmed, Amina, Amanullah, Farhana, Becerra, Mercedes C, Botgros, Radu, Brigden, Grania, Browning, Renee, Gardiner, Elizabeth, Hafner, Richard, Hesseling, Anneke, How, Cleotilde, Jean-Philippe, Patrick, Lessem, Erica, Makhene, Mamodikoe, Mbelle, Nontombi, Marais, Ben, McIlleron, Helen, Mc Neeley, David F, Mendel, Carl, Murray, Stephen, Navarro, Eileen, Oramasionwu, Gloria E, Porcalla, Ariel R, Powell, Clydette, Powell, Mair, Rigaud, Mona, Rouzier, Vanessa, Samson, Pearl, Schaaf, H. Simon, Shah, Seema, Starke, Jeff, Swaminathan, Soumya, Wobudeya, Eric, and Worrell, Carol

Subjects
new anti-TB drugs, Adult, Male, childhood TB, Clinical Trials as Topic, Consensus, Adolescent, drug resistant TB, Age Factors, Antitubercular Agents, Infant, Newborn, Infant, clinical trial, ethics, Article, Child, Preschool, Humans, Tuberculosis, Female, Child, pharmacokinetics
Abstract

Children represent a significant proportion of the global tuberculosis (TB) burden, and may be disproportionately more affected by its most severe clinical manifestations. Currently available treatments for pediatric drug-susceptible (DS) and drug-resistant (DR) TB, albeit generally effective, are hampered by high pill burden, long duration of treatment, coexistent toxicities, and an overall lack of suitable, child-friendly formulations. The complex and burdensome nature of administering the existing regimens to treat DS TB also contributes to the rise of DR TB strains. Despite the availability and use of these therapies for decades, a dearth of dosing evidence in children underscores the importance of sustained efforts for TB drug development to better meet the treatment needs of children with TB. Several new TB drugs and regimens with promising activity against both DS and DR TB strains have recently entered clinical development and are in various phases of clinical evaluation in adults or have received marketing authorization for adults. However, initiation of clinical trials to evaluate these drugs in children is often deferred, pending the availability of complete safety and efficacy data in adults or after drug approval. This document summarizes consensus statements from an international panel of childhood TB opinion leaders which support the initiation of evaluation of new TB drugs and regimens in children at earlier phases of the TB Drug development cycle.

Published
2015

8. The respiratory syncytial virus vaccine landscape : lessons from the graveyard and promising candidates

Author

Mazur, Natalie I., Higgins, Deborah, Nunes, Marta C., Melero, José A., Langedijk, Annefleur C., Horsley, Nicole, Buchholz, Ursula J., Openshaw, Peter J., McLellan, Jason S., Englund, Janet A., Mejias, Asuncion, Karron, Ruth A., Simões, Eric AF, Knezevic, Ivana, Ramilo, Octavio, Piedra, Pedro A., Chu, Helen Y., Falsey, Ann R., Nair, Harish, Kragten-Tabatabaie, Leyla, Greenough, Anne, Baraldi, Eugenio, Papadopoulos, Nikolaos G., Vekemans, Johan, Polack, Fernando P., Powell, Mair, Satav, Ashish, Walsh, Edward E., Stein, Renato T., Graham, Barney S., Bont, Louis J., Respiratory Syncytial Virus Network (ReSViNET) Foundation, Mazur, Natalie I., Higgins, Deborah, Nunes, Marta C., Melero, José A., Langedijk, Annefleur C., Horsley, Nicole, Buchholz, Ursula J., Openshaw, Peter J., McLellan, Jason S., Englund, Janet A., Mejias, Asuncion, Karron, Ruth A., Simões, Eric AF, Knezevic, Ivana, Ramilo, Octavio, Piedra, Pedro A., Chu, Helen Y., Falsey, Ann R., Nair, Harish, Kragten-Tabatabaie, Leyla, Greenough, Anne, Baraldi, Eugenio, Papadopoulos, Nikolaos G., Vekemans, Johan, Polack, Fernando P., Powell, Mair, Satav, Ashish, Walsh, Edward E., Stein, Renato T., Graham, Barney S., Bont, Louis J., and Respiratory Syncytial Virus Network (ReSViNET) Foundation

Published
2018

9. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates

Author

Infectieziekten onderzoek1 (Bont), Infectiezieken, CTI Bont, Child Health, Infection & Immunity, Mazur, Natalie I., Higgins, Deborah, Nunes, Marta C., Melero, José A., Langedijk, Annefleur C., Horsley, Nicole, Buchholz, Ursula J., Openshaw, Peter J., McLellan, Jason S., Englund, Janet A., Mejias, Asuncion, Karron, Ruth A., Simões, Eric AF, Knezevic, Ivana, Ramilo, Octavio, Piedra, Pedro A., Chu, Helen Y., Falsey, Ann R., Nair, Harish, Kragten-Tabatabaie, Leyla, Greenough, Anne, Baraldi, Eugenio, Papadopoulos, Nikolaos G., Vekemans, Johan, Polack, Fernando P., Powell, Mair, Satav, Ashish, Walsh, Edward E., Stein, Renato T., Graham, Barney S., Bont, Louis J., Respiratory Syncytial Virus Network (ReSViNET) Foundation, Infectieziekten onderzoek1 (Bont), Infectiezieken, CTI Bont, Child Health, Infection & Immunity, Mazur, Natalie I., Higgins, Deborah, Nunes, Marta C., Melero, José A., Langedijk, Annefleur C., Horsley, Nicole, Buchholz, Ursula J., Openshaw, Peter J., McLellan, Jason S., Englund, Janet A., Mejias, Asuncion, Karron, Ruth A., Simões, Eric AF, Knezevic, Ivana, Ramilo, Octavio, Piedra, Pedro A., Chu, Helen Y., Falsey, Ann R., Nair, Harish, Kragten-Tabatabaie, Leyla, Greenough, Anne, Baraldi, Eugenio, Papadopoulos, Nikolaos G., Vekemans, Johan, Polack, Fernando P., Powell, Mair, Satav, Ashish, Walsh, Edward E., Stein, Renato T., Graham, Barney S., Bont, Louis J., and Respiratory Syncytial Virus Network (ReSViNET) Foundation

Published
2018

11. Report from the World Health Organization's Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7–9th Sep 2015

Author

Giersing, Birgitte K., primary, Modjarrad, Kayvon, additional, Kaslow, David C., additional, Moorthy, Vasee S., additional, Bavdekar, Ashish, additional, Cichutek, Klaus, additional, Cravioto, Alejandro, additional, Fritzell, Bernard, additional, Graham, Barney S., additional, Karron, Ruth, additional, Lanata, Claudio F., additional, Powell, Mair, additional, Shao, Yiming, additional, and Smith, Peter, additional

Published
2016
Full Text
View/download PDF

12. Towards early inclusion of children in tuberculosis drugs trials: a consensus statement

Author

Nachman, Sharon, primary, Ahmed, Amina, additional, Amanullah, Farhana, additional, Becerra, Mercedes C, additional, Botgros, Radu, additional, Brigden, Grania, additional, Browning, Renee, additional, Gardiner, Elizabeth, additional, Hafner, Richard, additional, Hesseling, Anneke, additional, How, Cleotilde, additional, Jean-Philippe, Patrick, additional, Lessem, Erica, additional, Makhene, Mamodikoe, additional, Mbelle, Nontombi, additional, Marais, Ben, additional, McIlleron, Helen, additional, McNeeley, David F, additional, Mendel, Carl, additional, Murray, Stephen, additional, Navarro, Eileen, additional, Anyalechi, E Gloria, additional, Porcalla, Ariel R, additional, Powell, Clydette, additional, Powell, Mair, additional, Rigaud, Mona, additional, Rouzier, Vanessa, additional, Samson, Pearl, additional, Schaaf, H Simon, additional, Shah, Seema, additional, Starke, Jeff, additional, Swaminathan, Soumya, additional, Wobudeya, Eric, additional, and Worrell, Carol, additional

Published
2015
Full Text
View/download PDF

16. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates.

Author

Respiratory Syncytial Virus Network (ReSViNET) Foundation, Mazur, Natalie I, Bont, Louis J, Melero, José A, McLellan, Jason S, Englund, Janet A, Karron, Ruth A, Simões, Eric AF, Knezevic, Ivana, Piedra, Pedro A, Langedijk, Annefleur C, Walsh, Edward E, Vekemans, Johan, Higgins, Deborah, Powell, Mair, Satav, Ashish, Graham, Barney S, Nunes, Marta C, Chu, Helen Y, and Ramilo, Octavio

Subjects
*RESPIRATORY syncytial virus, *INFANTS, *GLYCOPROTEINS, *MONOCLONAL antibodies, *VACCINES
Abstract

The global burden of disease caused by respiratory syncytial virus (RSV) is increasingly recognised, not only in infants, but also in older adults (aged ≥65 years). Advances in knowledge of the structural biology of the RSV surface fusion glycoprotein have revolutionised RSV vaccine development by providing a new target for preventive interventions. The RSV vaccine landscape has rapidly expanded to include 19 vaccine candidates and monoclonal antibodies (mAbs) in clinical trials, reflecting the urgency of reducing this global health problem and hence the prioritisation of RSV vaccine development. The candidates include mAbs and vaccines using four approaches: (1) particle-based, (2) live-attenuated or chimeric, (3) subunit, (4) vector-based. Late-phase RSV vaccine trial failures highlight gaps in knowledge regarding immunological protection and provide lessons for future development. In this Review, we highlight promising new approaches for RSV vaccine design and provide a comprehensive overview of RSV vaccine candidates and mAbs in clinical development to prevent one of the most common and severe infectious diseases in young children and older adults worldwide. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

17. Assessing the potential of a candidate dengue vaccine with mathematical modeling.

Author

Beatty M, Boni MF, Brown S, Buathong R, Burke D, Coudeville L, Cummings DA, Edelman R, Farrar J, Focks DA, Gomes MG, Guignard A, Halstead S, Hombach J, Knerer G, Koelle K, Lam FC, Lang J, Longini I, Medlock J, Namgyal P, Powell M, Recker M, Rohani P, Standaert B, Struchiner C, Teyssou R, and Wearing H

Subjects
Humans, Dengue epidemiology, Dengue prevention & control, Dengue Vaccines administration & dosage, Dengue Vaccines immunology, Models, Statistical
Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results